ECTS2016 Cancer and Bone Oral Communications Oral Communications (18 abstracts)
Secreted YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases
Maria Bettencourt 1 , Arlindo Ferreira 1, , Irina Alho 1 , Ana Lúcia Costa 2 , Ana Rita Sousa 2 , André Mansinho 2 , Catarina Abreu 2 , Catarina Pulido 2 , Daniela Macedo 2 , Inês Vendrell 2 , Teresa Pacheco 1, , Luis Costa 1, & Sandra Casimiro 1
1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; 2Oncology Division, Hospital de Santa Maria – Centro Hospitalar Lisboa Norte, Lisboa, Portugal.
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock protein that has been implicated in all hallmarks of cancer. Elevated YB-1 protein levels were correlated with poor prognosis in several types of cancers, including breast cancer (BC). In BC, high YB-1 expression is a marker of decreased overall survival (OS) and distant metastasis-free survival across all subtypes. YB-1 is also secreted by different cell types and may act as an extracellular mitogen. Therefore, our aim was to evaluate the association between YB-1 serum levels and clinicopathological characteristics and clinical outcomes of patients with BC and bone metastases (BM). In this retrospective cohort study we included 44 patients diagnosed with BM from BC, which started therapy with bisphosphonates and had peripheral blood collected at the time of first treatment with bisphosphonates. YB-1 was quantified in serum using Human YBX1/YB1 Sandwich ELISA kit (LSBio), according to manufacturer’s instructions. Clinicopathological characteristics were tabulated according to YB-1 status and differences tested using Fisher exact test. Time to event outcomes were analysed using Cox models. YB-1 was detected in the serum of 22 patients (50%), and correlated with the presence of extra-bone metastases (P=0.044), but not with other relevant clinicopathological characteristics. A non-significant trend towards estrogen receptor-negativity and radiographically mixed BM lesions was also found. Multivariate analysis showed that positive serum YB-1 is a marker of faster bone disease progression (HR 3.29, 95% CI 1.13–9.60, P=0.029). No significant differences were observed concerning OS (HR 2.04, 95% CI 0.86–4.87, P=0.108), and time to development of skeletal-related events (HR 1.45, 95% CI 0.53–4.00, P=0.467), although patients with positive YB-1 in serum had decreased median time to events.
Our data suggests that positive YB-1 in serum of patients with BC and BM is a biomarker of a more aggressive disease, with faster bone disease progression.
Volume 5
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more